Cargando…

Endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood

BACKGROUND: New biomarkers that predict later neurodevelopmental morbidity are needed. This study evaluated the associations between umbilical cord serum erythropoietin (us-EPO) and neurodevelopmental morbidity by the age of 2–6.5 years in a Finnish cohort. METHODS: This study included 878 non-anoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Rancken, Elina J., Metsäranta, Marjo P. H., Gissler, Mika, Rahkonen, Leena K., Haataja, Leena M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411059/
https://www.ncbi.nlm.nih.gov/pubmed/34465877
http://dx.doi.org/10.1038/s41390-021-01679-0
_version_ 1784775236015620096
author Rancken, Elina J.
Metsäranta, Marjo P. H.
Gissler, Mika
Rahkonen, Leena K.
Haataja, Leena M.
author_facet Rancken, Elina J.
Metsäranta, Marjo P. H.
Gissler, Mika
Rahkonen, Leena K.
Haataja, Leena M.
author_sort Rancken, Elina J.
collection PubMed
description BACKGROUND: New biomarkers that predict later neurodevelopmental morbidity are needed. This study evaluated the associations between umbilical cord serum erythropoietin (us-EPO) and neurodevelopmental morbidity by the age of 2–6.5 years in a Finnish cohort. METHODS: This study included 878 non-anomalous children born alive in 2012 to 2016 in Helsinki University Hospitals and whose us-EPO concentration was determined at birth. Data of these children were linked to data from the Finnish Medical Birth Register and the Finnish Hospital Discharge Register. Neurodevelopmental morbidity included cerebral palsy, epilepsy, intellectual disability, autism spectrum disorder, sensorineural defects, and minor neurodevelopmental disorders. RESULTS: In the cohort including both term and preterm children, us-EPO levels correlated with gestational age (r = 0.526) and were lower in premature children. High us-EPO levels (>100 IU/l) were associated with an increased risk of severe neurodevelopmental morbidity (OR: 4.87; 95% CI: 1.05–22.58) when adjusted for the gestational age. The distribution of us-EPO levels did not differ in children with or without the later neurodevelopmental diagnosis. CONCLUSIONS: Although high us-EPO concentration at birth was associated with an increased risk of neurodevelopmental morbidity in early childhood, the role of us-EPO determination in clinical use appears to be minor. IMPACT: We determined whether endogenous umbilical cord serum erythropoietin would be a new useful biomarker to predict the risk of neurodevelopmental morbidity. This study evaluated the role of endogenous erythropoietin at birth in neurodevelopmental morbidity with a study population of good size and specific diagnoses based on data from high-quality registers. Although high umbilical cord serum erythropoietin concentration at birth was associated with an increased risk of neurodevelopmental morbidity in early childhood, the clinical value of erythropoietin determination appears to be minor.
format Online
Article
Text
id pubmed-9411059
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-94110592022-08-27 Endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood Rancken, Elina J. Metsäranta, Marjo P. H. Gissler, Mika Rahkonen, Leena K. Haataja, Leena M. Pediatr Res Population Study Article BACKGROUND: New biomarkers that predict later neurodevelopmental morbidity are needed. This study evaluated the associations between umbilical cord serum erythropoietin (us-EPO) and neurodevelopmental morbidity by the age of 2–6.5 years in a Finnish cohort. METHODS: This study included 878 non-anomalous children born alive in 2012 to 2016 in Helsinki University Hospitals and whose us-EPO concentration was determined at birth. Data of these children were linked to data from the Finnish Medical Birth Register and the Finnish Hospital Discharge Register. Neurodevelopmental morbidity included cerebral palsy, epilepsy, intellectual disability, autism spectrum disorder, sensorineural defects, and minor neurodevelopmental disorders. RESULTS: In the cohort including both term and preterm children, us-EPO levels correlated with gestational age (r = 0.526) and were lower in premature children. High us-EPO levels (>100 IU/l) were associated with an increased risk of severe neurodevelopmental morbidity (OR: 4.87; 95% CI: 1.05–22.58) when adjusted for the gestational age. The distribution of us-EPO levels did not differ in children with or without the later neurodevelopmental diagnosis. CONCLUSIONS: Although high us-EPO concentration at birth was associated with an increased risk of neurodevelopmental morbidity in early childhood, the role of us-EPO determination in clinical use appears to be minor. IMPACT: We determined whether endogenous umbilical cord serum erythropoietin would be a new useful biomarker to predict the risk of neurodevelopmental morbidity. This study evaluated the role of endogenous erythropoietin at birth in neurodevelopmental morbidity with a study population of good size and specific diagnoses based on data from high-quality registers. Although high umbilical cord serum erythropoietin concentration at birth was associated with an increased risk of neurodevelopmental morbidity in early childhood, the clinical value of erythropoietin determination appears to be minor. Nature Publishing Group US 2021-08-31 2022 /pmc/articles/PMC9411059/ /pubmed/34465877 http://dx.doi.org/10.1038/s41390-021-01679-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Population Study Article
Rancken, Elina J.
Metsäranta, Marjo P. H.
Gissler, Mika
Rahkonen, Leena K.
Haataja, Leena M.
Endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood
title Endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood
title_full Endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood
title_fullStr Endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood
title_full_unstemmed Endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood
title_short Endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood
title_sort endogenous erythropoietin at birth is associated with neurodevelopmental morbidity in early childhood
topic Population Study Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411059/
https://www.ncbi.nlm.nih.gov/pubmed/34465877
http://dx.doi.org/10.1038/s41390-021-01679-0
work_keys_str_mv AT ranckenelinaj endogenouserythropoietinatbirthisassociatedwithneurodevelopmentalmorbidityinearlychildhood
AT metsarantamarjoph endogenouserythropoietinatbirthisassociatedwithneurodevelopmentalmorbidityinearlychildhood
AT gisslermika endogenouserythropoietinatbirthisassociatedwithneurodevelopmentalmorbidityinearlychildhood
AT rahkonenleenak endogenouserythropoietinatbirthisassociatedwithneurodevelopmentalmorbidityinearlychildhood
AT haatajaleenam endogenouserythropoietinatbirthisassociatedwithneurodevelopmentalmorbidityinearlychildhood